Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

1,260

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

1,260 results for “Pharmacology”

Learn how ShareScore rates datasets ↗
zenodo28/100

Supplementary material 1 from: Kadushkin AG, Tahanovich AD, Movchan LV, Dziadzichkina VV, Levandovskaya OV, Shman TV (2022) Nortriptyline overcomes corticosteroid resistance in NK and NKT-like cells from peripheral blood of patients with chronic obstructive pulmonary disease. Research Results in Pharmacology 8(1): 59-70. https://doi.org/10.3897/rrpharmacology.8.75467

Table S1

opencc-zeroApr 2022View details →
zenodo28/100

Papers 2022 . Research Group Pharmacology and Toxicology. University of Antioquia

<p>Papers 2022 . Research Group Pharmacology and Toxicology. University of Antioquia</p>

opencc-by-4.0Sep 2022View details →
zenodo28/100

ASSESSMENT OF PHARMACOLOGICAL PROPERTIES OF A NEW PHYTOCOMPOSITION

Open the record for dataset details and reuse information.

opencc-by-4.0May 2024View details →
zenodo28/100

Network pharmacology combined with gene chip to explore the targets of sanguinarine in ovarian cancer

Open the record for dataset details and reuse information.

opencc-by-4.0Jun 2024View details →
zenodo28/100

ANALYSIS OF PHARMACOLOGICAL PROPERTIES OF ANTITUSSIVE DRUGS

Open the record for dataset details and reuse information.

opencc-by-4.0Jun 2024View details →
dryad28/100

Data from: Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors

S 47445 is a novel positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors (AMPA-PAM). S 47445 enhanced glutamate's action at AMPA receptors on human and rat receptors and was inactive at NMDA and kainate receptors. Potentiation did not differ among the different AMPA receptors subtypes (GluA1/2/4 flip and flop variants) (EC50 between 2.5–5.4 μM), except a higher EC50 value for GluA4 flop (0.7 μM) and a greater amount of potentiation on GluA1 flop. A low concentration of S 47445 (0.1 μM) decreased receptor response decay time of GluA1flop/GluA2flip AMPA receptors and increased the sensitivity to glutamate. Furthermore, S 47445 (0.1 and 0.3 μM) in presence of repetitive glutamate pulses induced a progressive potentiation of the glutamate-evoked currents from the second pulse of glutamate confirming a rapid-enhancing effect of S 47445 at low concentrations. The potentiating effect of S 47445 (1 μM) was concentration-dependently reversed by the selective AMPA receptor antagonist GYKI52466 demonstrating the selective modulatory effect of S 47445 on AMPA receptors. Using an AMPA-kainate chimera approach, it was confirmed that S 47445 binds to the common binding pocket of AMPA-PAMs. S 47445 did not demonstrate neurotoxic effect against glutamate-mediated excitotoxicity in vitro, in contrast significantly protected rat cortical neurons at 10 μM. S 47445 was shown to improve both episodic and spatial working memory in adult rodents at 0.3 mg/kg, as measured in the natural forgetting condition of object recognition and T-maze tasks. Finally, no deleterious effect on spontaneous locomotion and general behavior was observed up to 1000 mg/kg of S 47445 given acutely in rodents, neither occurrence of convulsion or tremors. Collectively, these results indicate that S 47445 is a potent and selective AMPA-PAM presenting procognitive and potential neuroprotective properties. This drug is currently evaluated in clinical phase 2 studies in Alzheimer's disease and in Major Depressive Disorder.

opencc-zeroDec 2016View details →
zenodo28/100

Figure 1 from: Pavliuk B, Stechyshyn I, Chubka M, Hroshovyi T (2021) Preclinical safety evaluation of drone brood homogenate and justification of pharmacological action. Pharmacia 68(4): 771-777. https://doi.org/10.3897/pharmacia.68.e70678

Figure 1 Relationships between metabolic syndrome, insulin resistance, pre-diabetes and type 2 diabetes mellitus.

opencc-by-4.0Oct 2021View details →
zenodo28/100

Supplementary material 1 from: Indradi RB, Pitaloka DAE, Suryani (2022) Network pharmacology to uncover potential anti-inflammatory and immunomodulatory constituents in Curcuma longa rhizome as complementary treatment in COVID-19. Pharmacia 69(4): 995-1003. https://doi.org/10.3897/pharmacia.69.e89799

Datasets of Network Pharmacology Process

opencc-zeroNov 2022View details →
zenodo28/100

Supplementary material 1 from: Rahmadi M, Ardianto C, Nurhan AD, Chasanah RA, Krismonika DI, Puspitasari AD, Suprapti B, Segaran S, Phan C-W, Khotib J (2022) Bisacodyl overcomes morphine-induced constipation by decreasing colonic Aquaporin-3 and Aquaporin-4 expression. Research Results in Pharmacology 8(4): 65-75. https://doi.org/10.3897/rrpharmacology.8.82242

The representative photos of feces with high water content and low water content

opencc-zeroNov 2022View details →
zenodo28/100

Supplementary material 1 from: Kozuharova E, Simeonov V, Batovska D, Stoycheva C, Valchev H, Benbassat N (2023) Chemical composition and comparative analysis of lavender essential oil samples from Bulgaria in relation to the pharmacological effects. Pharmacia 70(2): 395-403. https://doi.org/10.3897/pharmacia.70.e104404

Lavender essential oil from Bulgaria and its pharmacological effects

opencc-zeroJun 2023View details →
zenodo28/100

Fig. 5 in Hyperforin: A natural lead compound with multiple pharmacological activities

Fig. 5. The mechanisms of anti-tumor activity of hyperforin.

opennotspecifiedFeb 2023View details →
zenodo28/100

Fig. 4 in Hyperforin: A natural lead compound with multiple pharmacological activities

Fig. 4. The mechanisms of anti-dementia activity of hyperforin.

opennotspecifiedFeb 2023View details →
zenodo28/100

Fig. 1 in Hyperforin: A natural lead compound with multiple pharmacological activities

Fig. 1. The structure of hyperforin.

opennotspecifiedFeb 2023View details →
zenodo28/100

Fig. 6 in Hyperforin: A natural lead compound with multiple pharmacological activities

Fig. 6. The mechanisms of immune regulatory and anti-inflammatory activity of hyperforin.

opennotspecifiedFeb 2023View details →
zenodo28/100

Fig. 3 in Hyperforin: A natural lead compound with multiple pharmacological activities

Fig. 3. The mechanisms of anti-depression activity of hyperforin.

opennotspecifiedFeb 2023View details →
zenodo28/100

Fig. 2 in Alkaloids from Picrasma quassioides: An overview of their NMR data, biosynthetic pathways and pharmacological effects

Fig. 2. Structures of canthinone alkaloids isolated from P. quassioides.

opennotspecifiedJan 2022View details →
zenodo28/100

Fig. 1 in Alkaloids from Picrasma quassioides: An overview of their NMR data, biosynthetic pathways and pharmacological effects

Fig. 1. Structures of β-carboline alkaloids isolated from P. quassioides.

opennotspecifiedJan 2022View details →
zenodo28/100

Fig. 4 in Alkaloids from Picrasma quassioides: An overview of their NMR data, biosynthetic pathways and pharmacological effects

Fig. 4. The putative biosynthetic pathway of β-carboline and canthinone alkaloids.

opennotspecifiedJan 2022View details →
zenodo28/100

Fig. 3 in Alkaloids from Picrasma quassioides: An overview of their NMR data, biosynthetic pathways and pharmacological effects

Fig. 3. Structures of alkaloid dimers isolated from P. quassioide.

opennotspecifiedJan 2022View details →
zenodo28/100

Fig. 7 in Carvone and its pharmacological activities: A systematic review

Fig. 7. Risk-of-bias assessment of the trials in vitro included in this systematic review.

opennotspecifiedApr 2022View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record